Researchers sought to determine whether acalabrutinib would be safe and effective in patients with treatment-naïve CLL who declined or were in ineligible for chemotherapy.
Results of a secondary analysis on oncology-patient communications regarding FS and PP concerns were presented at the 2021 ASCO Annual Meeting.
A symptom-adapted physical activity intervention helped older adults with AML to maintain their physical function while undergoing induction chemotherapy.
Researchers sought to determine whether adding bortezomib to bendamustine-rituximab induction therapy would improve survival in patients with mantle cell lymphoma.
Researchers have identified various factors associated with mortality following a diagnosis with the COVID-19 virus among recipients of allogeneic and autologous HCT.
A team of investigators sought to evaluate outcomes following combination treatment with eprenetapopt and azacitadine in TP53-mutant myelodysplastic syndromes, as well as in oligoblastic acute myeloid leukemia.
Initial treatment of mantle cell lymphoma with lenalidomide and rituximab may result in significant complete response rates and durable lengths of remission.
Among patients with HIV-associated Burkitt lymphoma, intensive regimens containing rituximab may be linked to favorable survival outcomes.
Investigators assessed mortality rates and other outcomes in patients with hematologic malignancies and COVID-19 infection.
Among patients with blood cancers, genetic variant profiles may negatively affect allo-HSCT outcomes including leukemia-free survival and acute GVHD.
